DCAT Value Chain Insights: Abzena, Mabqi Partner for Antibody Services

Abzena, a San Diego, California-based CDMO of biologics and antibody drug conjugates, and Mabqi, an antibody-focused company, have entered an agreement that will integrate Mabqi’s antibody discovery capabilities with Abzena’s development and manufacturing services.

The partnership’s combined offerings will use Mabqi’s LiteMab antibody discovery studio for hit screening, characterization, and hit selection by using universal & pH-sensitive libraries to identify top lead candidates, and use Abzena’s capabilities for developability, cell-line development, process development, and GMP manufacturing. The capabilities apply to a broad range of modalities, including monoclonal antibodies (mAbs), mAb fragments, bi- and multi-specifics, and bioconjugates.

Click here to access the full article